Synthetic Efforts Towards Glycoconjugate-Based Vaccines Active Against Anthrax
O. Milhomme and C. Grandjean
Pages 291-311 (21)
Anthrax is an infectious disease associated with a high death rate in the absence of treatment. To be effective, antibiotics must
be administered early after infection and during a prolonged period, therefore, designing vaccines is a valuable alternative. With the currently
marketed anthrax vaccines being considered less than optimal, the development of novel formulations is strongly encouraged by
health and government authorities. Along this line the recent disclosure of the structure of several oligosaccharides expressed at the surface
of Bacillus anthracis, the etiological agent of anthrax, has boosted the development of a glycoconjugate-based vaccine. This review
describes the different strategies which have been envisaged to prepare these carbohydrate antigens as well as analogs thereof. The data
on antigenicity and immunology generated by these derivatives are also detailed. Finally, future prospects on the development of anthrax
glycoconjugate vaccines are discussed.
Carbohydrate antigen synthesis, anthrose, glycoconjugate vaccine, anthrax, Bacillus anthracis.
Unite Fonctionnalite et Ingenierie des Proteines, FRE CNRS 3478, Universite des Sciences et Techniques de Nantes, 2 rue de la Houssiniere, BP92208, F-44322 Nantes Cedex 3, France.